Targacept News

VP, CFO & Treasurer of Targacept Inc. Alan A Musso sells 37,223 shares of TRGT on 12/11/2009 at an average price of $21.53 a share.

Targacept, Inc. , a clinical-stage biopharmaceutical company developing a new class of drugs known as NNR TherapeuticsTM, today announced that it has initiated a Phase 2 clinical proof of concept trial of TC-5619 in cognitive dysfunction in schizophrenia.

The deal didn't look too bad. It certainly wouldn't have merited a 6% decline in the stock under normal circumstances.

A drug to treat depression that was created and patented by a team of University of South Florida researchers is poised to bring millions of dollars of royalties to the university.

Targacept has found a commercial development partner for its potential blockbuster depression treatment and what a partner with a deal announced early Thursday that could be worth more than a whopping $1 billion.

The deal for Phase II adjunctive depression candidate TC-5214 with Targacept Inc.

LONDON & WINSTON-SALEM, N.C.-- --AstraZeneca and Targacept, Inc. today announced a collaboration and license agreement for the global development and commercialization of TC-5214, Targacepta s late-stage investigational product for major depressive disorder .

Investors must wait until probably next year to find out exactly what the withdrawal of Abilify's European marketing application means for Targacept Inc.'s chances overseas with lead asset TC-5214 in adjunctive depression therapy.

Targacept will be added to the NASDAQ Biotechnology Index as of next Monday, Nov.

Targacept, Inc. , a clinical-stage biopharmaceutical company developing a new class of drugs known as NNR Therapeutics , announced that J. Donald deBethizy, Ph.D., President and Chief Executive Officer, is scheduled to present at the following conferences: -- 8th Annual BIO Investor Forum at the Palace Hotel in San Francisco at 2:00 p.m. Pacific ...

Main Category: Depression Also Included In: Clinical Trials / Drug Trials Article Date: 19 Oct 2009 - 1:00 PDT Targacept, Inc.

SALEM, N.C. Wall Street bulls stampeded Friday for shares in Targacept after the drug development company announced strong clinical trial results for its major depressive disorder treatment candidate.

A complete list of all headlines and biomedical stock developments can be found on BioMedReports.Com On 10/15/09, Targacept, Inc.

Targacept wowed analysts with newly released Phase IIb data for depression drug candidate TC-5214, making a big splash at a meeting of the Society for Neuroscience and causing shares in the company to shoot up 16percent Friday.

Targacept, Inc. , a clinical-stage biopharmaceutical company developing a new class of drugs known as NNR Therapeutics, today announced the presentation of data from its recently completed Phase 2b clinical trial of TC-5214 as an augmentation treatment in subjects with major depressive disorder, or MDD, who did not respond adequately to first-line ...

Targacept, Inc. announced today the pricing of an underwritten public offering of 2,200,000 shares of its common stock.

Sep 10, 2009 - Targacept, Inc. , a clinical-stage biopharmaceutical company developing a new class of drugs known as NNR Therapeutics, today confirmed plans to present data from its completed Phase 2b clinical trial of TC-5214 as an augmentation treatment for major depressive disorder at the Nicotinic Acetylcholine Receptors as Therapeutic Targets ...

Based on the aggregated intelligence of 135,000-plus investors participating in Motley Fool CAPS , the Fool's free investing community, small-cap biotech Targacept has received the dreaded one-star ranking .

Targacept, Inc. August 5, 2009, 5:00 pm ET Executives Don deBethizy - President and CEO Alan Musso - VP, CFO and Treasurer Geoffrey Dunbar - VP, Clinical Development and Regulatory Affairs Analysts Bret Holley - Oppenheimer and Company Juan Sanchez - Ladenburg Mark McKechnie - William Presentation Operator Welcome to the Targacept's Second Quarter ...

Targacept, Inc. August 5, 2009, 5:00 pm ET Executives Don deBethizy - President and CEO Alan Musso - VP, CFO and Treasurer Geoffrey Dunbar - VP, Clinical Development and Regulatory Affairs Analysts Bret Holley - Oppenheimer and Company Juan Sanchez - Ladenburg Mark McKechnie - William Presentation Operator Welcome to the Targacept's Second Quarter ...